LLY

Eli Lilly and Company

Healthcare · NYSE · Market cap $1059.4bn

$1,257.03

as of 16 Oct 2026, 3% below its 52-week high

Screens as well placed to keep growing its dividend, with low cut-risk signals. Its valuation looks somewhat extended against its own history.

These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.

Trailing yield: 0.53%Last 12 months of regular payments at today's price
Forward yield: 0.61%Each payment expected in the next 12 months, not the latest one doubled
Earnings cover: 4.6×Pays 22% of earnings
Cash cover: 3.5×Free cash flow over dividends paid
5y dividend growth: +15.2% a yearNo cut since FY2008
Next ex-dividend date: Estimated14 Nov 2026Quarterly dividend of about $1.73

Compared with US companies in Drug Manufacturers - General (9)

Trailing yield is lower than all 8 other US companies in Drug Manufacturers - General.
5y dividend growth (as paid) is higher than all 7 other US companies in Drug Manufacturers - General with a 5y growth figure.

Quality

High

Capacity to keep growing the dividend

Risk

Low

Signals of dividend-cut pressure

Trim

Moderate

How extended the valuation looks

Why Trim is 63

LLY against US companies in Drug Manufacturers - General (9)

Valuation against its own history

As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of LLY’s past readings.

P/E37.7×P93, poor for this measure
Yield0.5%P18, poor for this measure
FCF payout28.8%P0, good for this measure
Net debt / EBITDA3.54P9, good for this measure
DGR 5y15.2%P100, good for this measure
ROIC9.4%P99, good for this measure

Open valuation history

Forecast your income with the LLY dividend calculator

Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.